Novacyt S.A. Notice of Results (3393W)
April 17 2023 - 2:00AM
UK Regulatory
TIDMNCYT
RNS Number : 3393W
Novacyt S.A.
17 April 2023
Novacyt S.A.
("Novacyt", the "Company" or the "Group")
Notice of Full Year 2022 Results and Investor Presentation
Paris, France and Eastleigh, UK - 17 April 2023 - Novacyt S.A.
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, announces that it will report its audited
financial results for the year ended 31 December 2022 on Thursday,
27 April 2023.
Investor webinar
An investor webinar presentation by James McCarthy, Acting Chief
Executive Officer, and Steve Gibson, Group Finance Director, will
take place at 12.00pm BST on Thursday, 27 April 2023.
The webinar is open to all existing and potential investors and
will consist of a presentation followed by a Q&A session, held
on the Investor Meet Company platform. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 9.00am
the day before the meeting or at any time during the live
presentation. Automated French subtitling will be available
throughout the presentation.
Investors can sign up to Investor Meet Company for free and add
to meet NOVACYT S.A. via:
https://www.investormeetcompany.com/novacyt-sa/register-investor
Investors who already follow NOVACYT S.A. on the Investor Meet
Company platform will automatically be invited.
- End -
Contacts
Novacyt SA
James Wakefield, Non-Executive Chairman
James McCarthy, Acting Chief Executive Officer
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and
Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
Numis (Joint Broker)
James Black / Freddie Barnfield / Duncan Monteith
+44 (0)20 7260 1000
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick Petit
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com ; y.petit@allegrafinance.com
Walbrook PR
Paul McManus/ Stephanie Cuthbert/ Anna Dunphy
+44 (0)20 7933 8780
novacyt@walbrookpr.com
About Novacyt Group
Novacyt is an international diagnostics business delivering a
broad portfolio of in vitro and molecular diagnostic tests for a
wide range of infectious diseases, enabling faster, more accurate,
accessible testing to improve healthcare outcomes. The Company
provides customers with a seamless sample-to-result workflow using
its integrated and scalable instrumentation/solutions. The Company
specialises in the design, manufacture, and supply of real-time PCR
kits, reagents and a full range of laboratory and qPCR
instrumentation for molecular biology research and clinical use.
Novacyt offers one of the world's most varied and comprehensive
range of qPCR assays, covering human, veterinary, biodefence,
environmental, agriculture and food testing.
Novacyt is headquartered in Vélizy in France with offices in
Stokesley and Eastleigh, UK, and is listed on the London Stock
Exchange's AIM market ("NCYT") and on the Paris Stock Exchange
Euronext Growth ("ALNOV").
For more information, please refer to the website:
www.novacyt.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOREAELSFDXDEFA
(END) Dow Jones Newswires
April 17, 2023 02:00 ET (06:00 GMT)
Novacyt (LSE:NCYT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novacyt (LSE:NCYT)
Historical Stock Chart
From Jul 2023 to Jul 2024